| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0e155c80e389bab36317e870e27933b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5758cb83cb0c335537b17c114f74206b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6489 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-33 |
| filingDate |
2012-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a0c645668a7545dc5f28117047eae6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac8fcd6de154e168736688d3e2285f6d |
| publicationDate |
2013-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013345398-A1 |
| titleOfInvention |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| abstract |
The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) botulinum neurotoxin genes from all botulinum neurotoxin serotypes. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product is stable and proteolytically active. Methods of using the products of the invention are described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021125866-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11193931-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11357821-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114269932-A |
| priorityDate |
1993-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |